CPT code assignment is what decides if a cleared cardiac AI model actually makes it to patients. Authorization is just one gate. Payment is the other. Anumana’s path, built on research from the Mayo Clinic, is a perfect example of how this two-gate system works in the real world.
FDA Clearance and Reimbursement Separation
For authorization, most devices go through the FDA’s 510(k) pathway, which is all about proving your new tech is substantially equivalent to a “predicate device” that’s already out there. As Bakul Patel has pointed out, this FDA clearance process is totally separate from the reimbursement step. The two reviews are completely independent. Even after you clear both of those hurdles, you’re not done, you’re still on the hook for Post-Market Surveillance, which means the question of your device’s ongoing clinical utility never really goes away.
Anumana’s CPT Code Assignment
Anumana just got CPT codes for its ECG-AI, which is a huge step toward actually getting reimbursed. The whole program is based on research from the Mayo Clinic, and it’s the first time an ECG-AI has been given its own codes. Getting them isn’t simple. The AMA CPT code assignment process has several stages:
- Application submission to the AMA CPT Editorial Panel.
- Review by clinical specialty societies.
- Panel discussion and vote.
- Publication of new or revised codes.
Category I CPT codes are the permanent ones you eventually want to graduate to. Category III codes, which are temporary codes designed for emerging technologies, are what Anumana received. Getting into this category is the critical foot in the door for payment.
Peer Programs and Compliance Pathways
This isn’t a new playbook. HeartFlow and iRhythm Technologies have been down this road before with their own cardiac programs. For both of them, getting into clinics depended on securing code assignment, proving that FDA clearance alone is never enough.
HeartFlow’s FFR-CT
Take HeartFlow’s FFR-CT technology. It’s a program that applies AI to standard computed tomography (CT) scans to get a non-invasive read on coronary artery disease. They successfully got through both the FDA clearance process and the CPT code assignment gauntlet to get their product used and paid for. HeartFlow CPT code information
iRhythm Technologies’ Zio XT
Or look at iRhythm’s Zio XT patch, a wearable biosensor that doctors prescribe for continuous ECG monitoring over a period of days. The Zio XT secured both FDA clearance for the device and specific CPT codes for its use. Those codes are what make extended ECG monitoring financially viable for a practice. iRhythm Technologies reimbursement guide
Post-Clearance Compliance Requirements
Any product map that stops at FDA authorization is just fantasy. Reimbursement is a completely separate compliance gate, and it’s guarded by the Centers for Medicare & Medicaid Services (CMS), which sets the payment policies everyone else follows. So what do you actually need to do? Developers have to live and breathe CMS policies on coverage determinations and payment rates, which you can track in the Federal Register. Your compliance plan has to account for this payment gate, not just the device gate. This is where things like real-world evidence (RWE) come in. It’s not just for the FDA submission, it’s for building your story for the payers. You also have to know what you are. A simple Clinical Decision Support (CDS) tool might be unregulated, but a diagnostic AI like these cardiac models is a full-blown medical device, a distinction that changes everything about your strategy. Behind the scenes, investors are doing due diligence on your GMLP (Good Machine Learning Practice) compliance, and everyone expects a rock-solid Quality Management System (QMS), usually with an ISO 13485 certification to prove it. All these elements make up your total compliance posture.
Frequently Asked Questions
What is the relationship between FDA clearance and reimbursement for medical devices?
FDA clearance, typically via the 510(k) Pathway, establishes device authorization by assessing substantial equivalence to a predicate device. Reimbursement, facilitated by CPT code assignment, is a separate and independent process that determines payment for the technology. Bakul Patel’s commentary highlights this separation, indicating that these reviews operate independently.
How did Anumana secure reimbursement for its ECG-AI technology?
Anumana secured reimbursement by receiving CPT codes for its ECG-AI, making it the first ECG-AI with such codes. The Mayo Clinic provided the research context for this program. This CPT Code Assignment is critical for facilitating payment for the technology.
What is the process for obtaining CPT codes for emerging technologies?
The CPT code assignment process involves submitting an application to the AMA CPT Editorial Panel, followed by review from clinical specialty societies. After panel discussion and a vote, new or revised codes are published. Anumana’s codes, for example, fall into the Category III CPT codes, which are temporary for emerging technologies.
What role do CMS policies play in the reimbursement pathway for medical devices?
CMS (Centers for Medicare & Medicaid Services) governs payment policies, making it a critical compliance gate after FDA authorization. Device developers must understand CMS policies, including coverage determinations and payment rates, which are often published in the Federal Register. A pathway map stopping at authorization is incomplete without considering CMS policies for reimbursement.
